RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric... Read More
For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org
Together, we will defeat stomach cancer.
Together, we will defeat stomach cancer.
MORE INFODONATE